miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.

Autor: Wang F; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Lou JF; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Cao Y; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Shi XH; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Wang P; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Xu J; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Xie EF; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Xu T; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Sun RH; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Rao JY; Department of Pathology and Anatomic Pathology, Ronald Reagan Medical Center of UCLA, Santa Monica, CA, USA., Huang PW; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Pan SY; 1] Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [2] National Key Clinical Department of Laboratory Medicine, Nanjing Medical University, Nanjing, China., Wang H; Department of Respiratory, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jazyk: angličtina
Zdroj: Experimental & molecular medicine [Exp Mol Med] 2015 May 08; Vol. 47, pp. e162. Date of Electronic Publication: 2015 May 08.
DOI: 10.1038/emm.2015.17
Abstrakt: MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC). The aim of this study was to investigate the clinical significance of miR-638 in the evaluation of NSCLC patient prognosis in response to chemotherapy. First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. Second, serum miR-638 expression levels were detected in vivo by using nude mice xenograft models bearing SPC-A1 with and without cisplatin treatment. In the clinic, the serum miR-638 levels of 200 cases of NSCLC patients before and after chemotherapy were determined by quantitative real-time PCR, and the associations of clinicopathological features with miR-638 expression patterns after chemotherapy were analyzed. Our data helped in demonstrating that cisplatin induced apoptosis of the SPC-A1 cells in a dose- and time-dependent manner accompanied by increased miR-638 expression levels in the culture supernatants. In vivo data further revealed that cisplatin induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638 expression patterns after chemotherapy significantly correlated with lymph node metastasis. Moreover, survival analyses revealed that patients who had increased miR-638 levels after chemotherapy showed significantly longer survival time than those who had decreased miR-638 levels. Our findings suggest that serum miR-638 levels are associated with the survival of NSCLC patients and may be considered a potential independent predictor for NSCLC prognosis.
Databáze: MEDLINE
Externí odkaz: